These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 31865939)

  • 1. Control of rheumatoid arthritis with conventional disease-modifying antirheumatic drugs in a tertiary hospital in central South Africa.
    Carter RMN; Jansen van Rensburg BJ; Joubert G
    S Afr Med J; 2019 Dec; 110(1):27-31. PubMed ID: 31865939
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of use of specialty services on disease-modifying antirheumatic drug use in the treatment of rheumatoid arthritis in an insured elderly population.
    Shipton D; Glazier RH; Guan J; Badley EM
    Med Care; 2004 Sep; 42(9):907-13. PubMed ID: 15319617
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factors associated with initial or subsequent choice of biologic disease-modifying antirheumatic drugs for treatment of rheumatoid arthritis.
    Jin Y; Desai RJ; Liu J; Choi NK; Kim SC
    Arthritis Res Ther; 2017 Jul; 19(1):159. PubMed ID: 28679392
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination of disease-modifying antirheumatic drugs in the treatment of rheumatoid arthritis. A survey of Alabama rheumatologists.
    Baum SK; Tracy IC; Henderson EH; Alarcón GS
    Arthritis Care Res; 1991 Mar; 4(1):48-51. PubMed ID: 11188587
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Disease-modifying treatment for inflammatory rheumatism in sub-Saharan Africa: outcome at 6 months of 205 Senegalese patients with rheumatoid arthritis].
    Ndongo S; Pouye A; Lekpa FK; Bihéhé DM; Tiendrebeogo J; Ndao AC; Ka MM; Moreira Diop T
    Med Sante Trop; 2012; 22(4):385-9. PubMed ID: 23352953
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence of Rheumatoid Arthritis and Drug Dispensing Patterns Among Medicaid and Medicaid-Medicare Dually Eligible Beneficiaries in Puerto Rico.
    Hernández-Muñoz JJ; Wei W; Sierra-Zorita R
    Arthritis Care Res (Hoboken); 2021 Feb; 73(2):199-206. PubMed ID: 32475025
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Determinants of adherence to disease modifying anti-rheumatic drugs in White British and South Asian patients with rheumatoid arthritis: a cross sectional study.
    Kumar K; Raza K; Nightingale P; Horne R; Chapman S; Greenfield S; Gill P
    BMC Musculoskelet Disord; 2015 Dec; 16():396. PubMed ID: 26714853
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identifying factors associated with concordance with the American College of Rheumatology rheumatoid arthritis treatment recommendations.
    Harrold LR; Reed GW; Kremer JM; Curtis JR; Solomon DH; Hochberg MC; Kavanaugh A; Saunders KC; Shan Y; Spruill TM; Pappas DA; Greenberg JD
    Arthritis Res Ther; 2016 Apr; 18():94. PubMed ID: 27118040
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antirheumatic Medicine Prescribing Patterns and Direct Medicine Costs in the South African Private Health Sector.
    Olivier N; Lubbe M; Joubert R; Naudé A; Burger J
    Value Health Reg Issues; 2018 Sep; 16():99-105. PubMed ID: 30227362
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Practical progress in realisation of early diagnosis and treatment of patients with suspected rheumatoid arthritis: results from two matched questionnaires within three years.
    Aletaha D; Eberl G; Nell VP; Machold KP; Smolen JS
    Ann Rheum Dis; 2002 Jul; 61(7):630-4. PubMed ID: 12079906
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Contemporary patterns of care and disease activity outcome in early rheumatoid arthritis: the ERAN cohort.
    Kiely P; Williams R; Walsh D; Young A;
    Rheumatology (Oxford); 2009 Jan; 48(1):57-60. PubMed ID: 18984608
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Primary care physicians' perspectives towards managing rheumatoid arthritis: room for improvement.
    Garneau KL; Iversen MD; Tsao H; Solomon DH
    Arthritis Res Ther; 2011; 13(6):R189. PubMed ID: 22098699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tocilizumab in patients with active rheumatoid arthritis and inadequate response to disease-modifying antirheumatic drugs or tumor necrosis factor inhibitors: subanalysis of Spanish results of an open-label study close to clinical practice.
    Álvaro-Gracia JM; Fernández-Nebro A; García-López A; Guzmán M; Blanco FJ; Navarro FJ; Bustabad S; Armendáriz Y; Román-Ivorra JA;
    Reumatol Clin; 2014; 10(2):94-100. PubMed ID: 24099961
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Economic Burden and Treatment Patterns of Cycling between Conventional Synthetic Disease-modifying Antirheumatic Drugs Among Biologic-treated Patients with Rheumatoid Arthritis.
    Betts KA; Griffith J; Ganguli A; Li N; Douglas K; Wu EQ
    Clin Ther; 2016 May; 38(5):1205-16. PubMed ID: 27045991
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Update on the prevalence and incidence of rheumatoid arthritis in Korea and an analysis of medical care and drug utilization.
    Won S; Cho SK; Kim D; Han M; Lee J; Jang EJ; Sung YK; Bae SC
    Rheumatol Int; 2018 Apr; 38(4):649-656. PubMed ID: 29302803
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Examining Time to Initiation of Biologic Disease-modifying Antirheumatic Drugs and Medication Adherence and Persistence Among Texas Medicaid Recipients With Rheumatoid Arthritis.
    Kim G; Barner JC; Rascati K; Richards K
    Clin Ther; 2016 Mar; 38(3):646-54. PubMed ID: 26899313
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study.
    Genovese MC; McKay JD; Nasonov EL; Mysler EF; da Silva NA; Alecock E; Woodworth T; Gomez-Reino JJ
    Arthritis Rheum; 2008 Oct; 58(10):2968-80. PubMed ID: 18821691
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.
    Chen YF; Jobanputra P; Barton P; Jowett S; Bryan S; Clark W; Fry-Smith A; Burls A
    Health Technol Assess; 2006 Nov; 10(42):iii-iv, xi-xiii, 1-229. PubMed ID: 17049139
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High variability in glucocorticoid starting doses in patients with rheumatoid arthritis: observational data from an early arthritis cohort.
    Albrecht K; Callhoff J; Schneider M; Zink A
    Rheumatol Int; 2015 Aug; 35(8):1377-84. PubMed ID: 25663291
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Medication effectiveness with the use of tumor necrosis factor inhibitors among Texas Medicaid patients diagnosed with rheumatoid arthritis.
    Oladapo A; Barner JC; Lawson KA; Novak S; Rascati KL; Richards KM; Harrison DJ
    J Manag Care Spec Pharm; 2014 Jul; 20(7):657-67. PubMed ID: 24967519
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.